Source: Pharmacy Times articles
An expert discusses the promising results of elranatamab as a consolidative therapy for relapsed/refractory multiple myeloma, enhancing patient outcomes.
Recent Content
- Regulation of stress tolerance by CREB1 sustains multiple myeloma cell survival
- (no title)
- (no title)
- (no title)
- (no title)
- (no title)
- (no title)
- (no title)
- Daily pill to stop pancreatic cancer spread granted FDA orphan drug status
- CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy